(RTTNews) – Endo International plc (ENDP), said Friday that its subsidiary, Par Sterile Products LLC, signed a non-exclusive agreement with Novavax Inc. to supply full production at its Rochester, Michigan plant for NVX-CoV2373. Novavax COVID-19 vaccine candidate. The financial and other terms of the agreement remain un disclosing.
According to the agreement, the installation of Par Sterile in Rochester has begun production of the latest pharmaceutical product NVX-CoV2373, and the initial batches will be used in Novavax’s fundamental Phase 3 clinical trial in the United States. NVX-CoV2373 vaccine for advertising distribution in the United States.
NVX-CoV2373 is a candidate vaccine designed from the genetic series of SARS-CoV-2, the COVID-19 disease virus.
NVX-CoV2373 is undergoing several Phase 2 clinical trials lately. A Phase 2 clinical trial to evaluate the protection and immunogenicity of NVX-CoV2373 began in August 2020 in the United States and Australia, based on positive Phase 1 effects and expanding to come with a phase 2b clinical trial in South Africa in August 2020 to evaluate efficacy.
The company expects provisional knowledge of these tests to be completed until the end of 2020.